Healio’s continuing coverage of the American Society of Hematology’s annual meeting made up some of the other top stories. These included data that suggested efgartigimod (argenx) was effective in primary immune thrombocytopenia and that mosunetuzumab (Genentech) induced remissions in advanced non-Hodgkin lymphoma. Read more . . .
The FDA granting orphan drug designation to a pancreatic cancer product was one of the top stories in hematology and oncology last week.